Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enzo Biochem Presents New AmpiProbe™ Nucleic Acid Amplification Platform

Published: Monday, April 02, 2012
Last Updated: Monday, April 02, 2012
Bookmark and Share
Data suggests highly efficient and economic platform could be basis for next-generation molecular diagnostics.

Enzo Biochem Inc. announced that the Company has made its first peer-reviewed presentation of its novel AmpiProbe™ platform, encompassing low cost, and high sensitivity, real time nucleic acid amplification and detection assays, at the annual meeting in London of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

The Company’s presentation, titled “Quantitative Detection of HCV RNA in Human Plasma-Serum using the Enzo AmpiProbe™ HCV RNA Assay,” detailed the specifications and performance characteristics of the first diagnostic product developed utilizing the AmpiProbe™ platform.

“The assay is the first product based on our next-generation molecular diagnostics platform,” said Elazar Rabbani, CEO of Enzo Biochem. “Our plan is to systematically introduce a number of additional products that could deliver a panel of relevant diagnostics that can be performed simultaneously from a single clinical sample, a program now underway. The objective is to develop assays that are expected to provide a cost-effective solution to clinical labs while providing physicians with more comprehensive medical information on a highly economic and time consuming basis.”

Enzo‘s AmpiProbe™ Hepatitis C virus RNA assay was tested over hundreds of clinical samples and found to be reproducible, accurate and precise, the presentation indicated. The assay was found to be highly specific to HCV, showing no cross reactivity to other infectious viruses and no susceptibility to potentially interfering substances associated with clinical samples. In addition, the AmpiProbe™ HCV RNA assay was found, as compared to similar diagnostics products, to achieve a greater enhanced sensitivity that allows for a more convenient and efficient workflow requiring significantly less starting material. The data also suggests that it may facilitate paneling of multiple independent assays from the standard amount of starting material.

The Company recently announced that it had completed a submission to the New York State Department of Health seeking approval to utilize this assay as a laboratory developed test and that it also has commenced the process for obtaining CE-IVD (Conformité Européenne in vitro diagnostic) designation, which would allow it to market its HCV RNA assay as a diagnostic product in the European Union.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Enzo Clinical Lab and DiaSorin Collaborate
The collaboration will enable the DiaSorin to provide physician-clients in metropolitan New York with advanced diagnostic tools.
Friday, October 18, 2013
Enzo and NIH File Patent Application for Autoimmune Diseases
Collaborators filed a patent application for the management of autoimmune diseases that may include age-related macular degeneration (AMD), which is a leading cause of blindness in the United States.
Thursday, May 09, 2013
Enzo Biochem Announces Expanded Distribution Agreement with Japan’s Cosmo Bio
Under the terms of the arrangement, Cosmo Bio will assume a leadership position in Japan in the promotion, sales, and high level technical and customer support for Enzo Life Sciences products.
Wednesday, March 21, 2012
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!